Edgewise Therapeutics Inc (NASDAQ:EWTX) — Market Cap & Net Worth
Market Cap & Net Worth: Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics Inc (NASDAQ:EWTX) has a market capitalization of $3.66 Billion ($3.66 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4343 globally and #1501 in its home market, demonstrating a 1.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Edgewise Therapeutics Inc's stock price $43.63 by its total outstanding shares 107593006 (107.59 Million). Also see Edgewise Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Edgewise Therapeutics Inc Market Cap History: 2021 to 2026
Edgewise Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows growth from $1.64 Billion to $4.69 Billion (7.08% CAGR). Also see EWTX cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Edgewise Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.14% | #110 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.01% | #500 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.19% | #70 of 263 |
Weight: Edgewise Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Edgewise Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Edgewise Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Edgewise Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EWTX by Market Capitalization
Companies near Edgewise Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review Edgewise Therapeutics Inc (EWTX) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Edgewise Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Edgewise Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Edgewise Therapeutics Inc's market cap moved from $1.64 Billion to $ 4.69 Billion, with a yearly change of 7.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.69 Billion | +75.82% |
| 2025 | $2.67 Billion | -7.06% |
| 2024 | $2.87 Billion | +144.06% |
| 2023 | $1.18 Billion | +22.37% |
| 2022 | $961.88 Million | -41.49% |
| 2021 | $1.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Edgewise Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.66 Billion USD |
| MoneyControl | $3.66 Billion USD |
| MarketWatch | $3.66 Billion USD |
| marketcap.company | $3.66 Billion USD |
| Reuters | $3.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more